Company / Free Cash Flow
Aclaris Therapeutics, Inc. Free Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$47.2M
FY2025
5-year range
-$79.6M / -$47.2M
FY2021-FY2025
Trend
+40.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has fluctuated over the past 9 years, ranging from -$102M in FY2020 to -$21M in FY2017.
Based on SEC 10-K filings.
-$47M in FY2025.
Improved from -$52M to -$47M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 40.7% year-over-year.
- Peak free cash flow was recorded in FY2017.
- Lowest free cash flow in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$47.2M | +40.7% |
| FY2024 | -$79.6M | -51.9% |
| FY2023 | -$52.4M | +23.1% |
| FY2022 | -$68.2M | -30.0% |
| FY2021 | -$52.4M | +48.7% |
| FY2020 | -$102.2M | -82.8% |
| FY2019 | -$55.9M | +45.3% |
| FY2018 | -$102.2M | -389.4% |
| FY2017 | -$20.9M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026